Liver and kidney transplant recipients have a higher risk of severe COVID-19 and/or death should they become infected because the medication they take to ensure a successful transplant suppresses their immune systems.

Keck Hospital of USC performs some 300 liver and kidney transplants each year, and provides ongoing care to thousands of post-transplant patients on an outpatient basis. During the peak of the COVID-19 surge in Los Angeles, Keck Medicine of USC physicians implemented a new protocol to monitor and manage the care of liver and kidney transplant recipients who developed COVID-19, including monoclonal antibody therapy for eligible patients.

To continue reading this story, click here.